Axsome Therapeutics
AXSM
256 hedge funds and large institutions have $3.28B invested in Axsome Therapeutics in 2024 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 78 increasing their positions, 96 reducing their positions, and 33 closing their positions.
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
10% more call options, than puts
Call options by funds: $50M | Put options by funds: $45.3M
6% more capital invested
Capital invested by funds: $3.09B → $3.28B (+$186M)
3.94% more ownership
Funds ownership: 81.8% → 85.75% (+3.9%)
0% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 33
1% less funds holding
Funds holding: 259 → 256 (-3)
19% less repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 96
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$70.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$52.2M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$43.8M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$40.6M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$29.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$47.8M |
| 2 |
Morgan Stanley
New York
|
-$46M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$28.9M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$25.8M |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$23.5M |
AXSM Hedge Fund Activity: Q2 2024 in Review
256 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2024, worth a combined $3.28B — up 6% from $3.09B a quarter earlier.
Fund positioning in AXSM was balanced in Q2 2024: 33 funds opened new positions, 33 closed out, 78 added to existing stakes and 96 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $70.7M. The largest seller was Perceptive Advisors, cutting an estimated $47.8M.
- 256 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2024, down from 259 in Q1 2024.
- Funds reported $3.28B of Axsome Therapeutics stock for Q2 2024, up 6% quarter-over-quarter.
- 33 funds opened new Axsome Therapeutics positions in Q2 2024 and 33 closed out, a net change of 0 holders.
- The largest Axsome Therapeutics buyer in Q2 2024 was BVF Inc, an estimated $70.7M added.
- The largest Axsome Therapeutics seller in Q2 2024 was Perceptive Advisors, an estimated $47.8M sold.
Based on aggregated 13F filings for Q2 2024.